Skip to main content

Investigational drugs reduce risk of death from Ebola virus disease

Submitted by lsekela on December 2, 2019 - 12:16 PM

Investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). 

Content Source:

US National Institute of Allergy and Infectious Diseases (NIAID)

Content Author: